Clinical trials: Tenosynovial Giant Cell Tumor
Tenosynovial Giant Cell Tumor
A Study of DCC-3014 to Evaluate the Efficacy, Safety, and Pharmacokinetics in Subjects With TGCT
To evaluate the efficacy, safety, and pharmacokinetics of DCC-3014 in subjects with Tenosynovial Giant Cell Tumor
- Trial name
- NCT07832747
- Testing
- DCC-3014
- Where
- Japan
- Volunteers
- 18 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Synovitis Villonodular
Synovial Tissue as a Biomarker in the Management of Pigmented Villonodular Synovitis
Pigmented villonodular synovitis (PVNS) is a rare joint disease caused by the proliferation of synovial tissue, leading to significant pain and joint destruction.
- Trial name
- SYVIPRO (NCT07503821)
- Testing
- synovial biopsy
- Where
- 3 sites in France
- Volunteers
- 30 people
- Sponsor
- Nantes University Hospital
Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis
A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients
The purpose of this Phase 2, open-label, multiple-dose, dose-escalation study is to evaluate intravenous AMB-05X in the treatment of subjects with TGCT.
- Conditions
- Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, TGCT, PVNS - Pigmented Villonodular Synovitis
- Trial name
- NCT04938180
- Testing
- AMB-05X
- Where
- 5 sites in Hungary, Poland and 1 more
- Volunteers
- 4 people
- Sponsor
- AmMax Bio, Inc.
Pigmented Villonodular Synovitis, Giant Cell Tumors of the Tendon Sheath
Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)
This is a Phase 3 clinical study, which aims to evaluate the effectiveness of an investigational drug called pexidartinib for the treatment of certain tumors for which surgical removal could cause more harm than good.
- Conditions
- Pigmented Villonodular Synovitis, Giant Cell Tumors of the Tendon Sheath, Tenosynovial Giant Cell Tumor
- Trial name
- ENLIVEN (NCT02371369)
- Testing
- Pexidartinib
- Where
- 39 sites in United States, Australia and 10 more
- Volunteers
- 120 people
- Sponsor
- Daiichi Sankyo
Pigmented Villonodular Synovitis, TGCT
A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT
AMB-051-07 is an open-label, adaptive, dose-ranging study with long-term extension in adults with tenosynovial giant cell tumor
- Conditions
- Pigmented Villonodular Synovitis, TGCT, Tenosynovial Giant Cell Tumor
- Trial name
- NCT05349643
- Testing
- AMB-05X
- Where
- 6 sites in United States, Australia and 1 more
- Volunteers
- 20 people
- Sponsor
- AmMax Bio, Inc.
Tenosynovial Giant Cell Tumor
Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)
The primary purpose of this study is to assess the tolerability, pharmacokinetics, and efficacy of pimicotinib in Japanese participants with TGCT
- Trial name
- NCT07499362
- Testing
- Pimicotinib
- Where
- 4 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Pigmented Villonodular Synovitis, PVNS
MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)
This study, designed as a proof of concept study of MCS110 in pigmented villonodular synovitis, assessed the clinical response to MCS110 treatment in Pigmented Villonodular Synovitis (PVNS) patients, after a single or multiple…
- Conditions
- Pigmented Villonodular Synovitis, PVNS, Giant Cell Tumor of the Tendon Sheath, GCCTS
- Trial name
- NCT01643850
- Testing
- MCS110
- Where
- 8 sites in United States, Switzerland
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Tenosynovial Giant Cell Tumor
Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib
This study is designed to evaluate the discontinuation/re-treatment of pexidartinib therapy in previously treated participants with tenosynovial giant cell tumor (TGCT).
- Trial name
- PLX3397 (NCT04526704)
- Testing
- Pexidartinib
- Where
- 16 sites in United States, Australia and 5 more
- Volunteers
- 32 people
- Sponsor
- Daiichi Sankyo
Tenosynovial Giant Cell Tumor
A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan
This phase 2, multicenter, two-part, open-label, single-arm study will be conducted in Japan and will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of pexidartinib in adult participants with symptomatic…
- Trial name
- NCT04703322
- Testing
- Pexidartinib
- Where
- 6 sites in Japan
- Volunteers
- 9 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis (PVNS)
An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee
AMB-051-01 is a multicenter study with an adaptive design that will enroll subjects with Tenosynovial Giant Cell Tumor (TGCT) of the knee for 12 weeks of multiple-dose, open-label treatment with intra-articular AMB-05X.
- Trial name
- NCT04731675
- Testing
- AMB-05X
- Where
- 6 sites in United States, Netherlands and 2 more
- Volunteers
- 11 people
- Sponsor
- AmMax Bio, Inc.
Hepatotoxicity, Tenosynovial Giant Cell Tumor
A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment
A study to evaluate the long-term risk of hepatic failure with TURALIO™ (pexidartinib) and the mechanism of liver injury based upon optional liver biopsy information among patients who received or are receiving TURALIO™…
- Trial name
- NCT04635111
- Testing
- TURALIO™
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Daiichi Sankyo
Solid Tumors, Tenosynovial Giant Cell Tumor
A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor
The purpose of this research study is to evaluate safety, pharmacokinetics and preliminary efficacy of the investigational drug PLX73086 in subjects with solid tumors including subjects with locally advanced or refractory…
- Conditions
- Solid Tumors, Tenosynovial Giant Cell Tumor, Synovitis, Pigmented Villonodular
- Trial name
- NCT02673736
- Testing
- PLX73086
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Plexxikon
Pigmented Villonodular Synovitis, Tenosynovial Giant Cell Tumor
Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor
This is a phase 1/2 single arm, open-label, safety, tolerability, and PK study of cabiralizumab in PVNS/dt-TGCT patients.
- Trial name
- FPA008-002 (NCT02471716)
- Testing
- FPA008
- Where
- 12 sites in United States, France and 4 more
- Volunteers
- 66 people
- Sponsor
- Five Prime Therapeutics, Inc.
Solid Tumor, Tumors of Any Histology With Activating Trk (NTRK) Point or NTRK Fusion Mutations
Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors
The objective of this study is to determine the safety, pharmacokinetics, maximum tolerated dose/recommended Phase 2 dose, and efficacy of PLX7486.
- Conditions
- Solid Tumor, Tumors of Any Histology With Activating Trk (NTRK) Point or NTRK Fusion Mutations, Tenosynovial Giant Cell Tumor
- Trial name
- NCT01804530
- Testing
- PLX7486 TsOH
- Where
- 4 sites in United States
- Volunteers
- 59 people
- Sponsor
- Plexxikon